# Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.

> **NCT06201611** · PHASE2,PHASE3 · RECRUITING · sponsor: **St. John's Research Institute** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Neuropathy Peripheral

## Interventions

- **DRUG:** Nebivolol+ Standard care arm
- **DRUG:** Epalrestat + Alpha Lipoic Acid +Standard care
- **DRUG:** Standard care alone

## Key facts

- **NCT ID:** NCT06201611
- **Lead sponsor:** St. John's Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06201611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06201611, "Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06201611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*